Serial biotech acquirer Concentra Biosciences, led by investor Kevin Tang, finalized a deal to acquire struggling cell therapy company Cargo Therapeutics. Cargo had faced significant challenges including safety setbacks, pipeline suspensions, layoffs, and leadership changes. The acquisition includes cash consideration and contingent value rights, marking another move in Concentra's aggressive spree targeting underperforming or distressed biotech firms this year.